Zeidner, Joshua F. http://orcid.org/0000-0002-9014-1514
Knaus, Hanna A.
Zeidan, Amer M.
Blackford, Amanda L.
Montiel-Esparza, Raul
Hackl, Hubert http://orcid.org/0000-0003-4055-3841
Prince, Gabrielle T.
Gondek, Lukasz P.
Ghiaur, Gabriel
Showel, Margaret M.
DeZern, Amy E.
Pratz, Keith W.
Douglas Smith, B.
Levis, Mark J. http://orcid.org/0000-0003-0473-6982
Gore, Steven
Coombs, Catherine C.
Foster, Matthew C.
Streicher, Howard
Karp, Judith E.
Luznik, Leo
Gojo, Ivana
Funding for this research was provided by:
Leukemia and Lymphoma Society
U.S. Department of Health & Human Services | NIH | National Cancer Institute (5-UM1-CA186704, UM1-CA-186691)
American Society for Blood and Marrow Transplantation
Gabrielle's Angel Foundation for Cancer Research
U.S. Department of Health & Human Services | NIH | National Cancer Institute
Article History
Received: 23 July 2019
Revised: 24 November 2019
Accepted: 6 December 2019
First Online: 3 January 2020
Compliance with ethical standards
:
: JFZ reports receiving research funding from Celgene, Merck, Takeda, and Tolero Pharmaceuticals, honoraria from AbbVie, Agios, Celgene, Daiichi Sankyo, Genentech, Pfizer, and Tolero Pharmaceuticals, and has served as a consultant for AsystBio Laboratories, Celgene, Covance, and Takeda. AMZ reports receiving research funding (institutional) from Celgene, Acceleron, Abbvie, Otsuka, Pfizer, Medimmune/AstraZeneca, Boehringer-Ingelheim, Trovagene, Incyte, Takeda, and ADC Therapeutics, consultancy with and received honoraria from AbbVie, Otsuka, Pfizer, Jazz, Celgene, Ariad, Incyte, Agios, Boehringer-Ingelheim, Novartis, Acceleron, Astellas, Daiichi Sankyo, Cardinal Health, Seattle Genetics, BeyondSpring, and Takeda. None of these relationships were related to the development of this manuscript. BDS reports being on Data Safety Monitoring Board for Celgene and has served as a consultant for Agios, Bristol-Myers Squibb, Jazz, Novartis, and Pfizer. MJL reports receiving research funding from Astellas, FujiFilm, and Novartis, and has served as a consultant for Agios, Amgen, Astellas, Daiichi Sankyo, FujiFilm, Karyopharm, Menarini, and Novartis. CCC has received honoraria from Abbvie, Loxo, Pharmacyclics, Octapharma, and H3 Biomedicine, has served as a consultant for Abbvie, Covance, and Cowen & Co., and has received institutional funding from Incyte, Gilead, AROG, Loxo, and H3 Biomedicine. LL has received research support from Genentech and Merck and has a patent licensed to WindMIL Therapeutics (WO2014085437A2). IG received research funding from Merck and Amgen, and participated in the advisory board meetings for Amgen, Jazz, Novartis and Abbvie. None of these relationships were related to the development of this manuscript. All other authors declare no conflict of interest.